Therapy for metastatic melanoma: an overview and update.
about
PLGA-loaded nanomedicines in melanoma treatment: Future prospect for efficient drug deliveryBurden of illness for metastatic melanoma in Canada, 2011-2013A possible cross-talk between autophagy and apoptosis in generating an immune response in melanomaRUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.Resource utilization and costs of managing patients with advanced melanoma: a Canadian population-based study.Perspectives on the application of nanotechnology in photodynamic therapy for the treatment of melanomaIpilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.Quantitative label-free mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue representing the invasive cutaneous malignant melanoma proteome.Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.MiR-7a is an important mediator in Fas-associated protein with death domain (FADD)-regulated expression of focal adhesion kinase (FAK).Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics.A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration.Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathwayRIN1 exhibits oncogenic property to suppress apoptosis and its aberrant accumulation associates with poor prognosis in melanoma.Electrochemotherapy: an effective local treatment of cutaneous and subcutaneous melanoma metastases.Galangin inhibits tumor growth and metastasis of B16F10 melanoma.Dietary Crocin Reverses Melanoma Metastasis.Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor).The age of enlightenment in melanoma immunotherapySinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition
P2860
Q28076905-9EBBD65F-ADD0-4D9C-9A55-A142EC87BA29Q28354125-14F5C926-EE8A-40EC-832B-BC67A4E99418Q30416873-D98FCC8B-4B6B-4156-AB8B-0FFA7F798E7AQ33697210-0FC48C7F-77A1-4DEE-9CB3-602370049075Q33840135-D41BD345-E66B-4894-9CF8-CE4AB2AD9FFDQ34123491-01E98AF0-F1D4-41EC-9445-FA732290856BQ35688401-7693B33A-AA42-4B18-9E59-EE19F95034C5Q36207327-CE0D8AD1-6737-4399-B1C5-2C2E0D9A399CQ37069163-B002EC2B-52CF-4396-9ADC-25A3AD5551B6Q37588295-AF658A7D-8EC7-4055-BC60-3A2946D8BB56Q38127412-8C653476-4D74-40C3-893C-2A06845F3AD7Q38593792-013228E2-9363-4827-A530-113207DD6162Q38815463-51EF0F95-BF64-4633-83E4-9CE51E840C6FQ39018168-8E1CCF4D-19BB-4EAB-852F-A4434B371179Q39342568-2B7D88B5-1381-489D-80BB-2C25E284688BQ46057463-060E59D5-73FD-4977-A68A-9EA62480B3E7Q47271594-AB63C145-2382-4FA8-9FF6-22FB51AE2635Q50007474-8D090E2E-6B49-4993-8C9A-DD1B457F9138Q55492453-38378F6A-7172-4489-8A6F-BC60354D6589Q58724285-B527D8A9-7261-4AAC-8729-7B805F00A496Q58799263-5FD7DB27-E41F-4194-A5EE-29845ADA843A
P2860
Therapy for metastatic melanoma: an overview and update.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapy for metastatic melanoma: an overview and update.
@en
Therapy for metastatic melanoma: an overview and update.
@nl
type
label
Therapy for metastatic melanoma: an overview and update.
@en
Therapy for metastatic melanoma: an overview and update.
@nl
prefLabel
Therapy for metastatic melanoma: an overview and update.
@en
Therapy for metastatic melanoma: an overview and update.
@nl
P2860
P356
P1476
Therapy for metastatic melanoma: an overview and update.
@en
P2860
P304
P356
10.1586/ERA.11.25
P577
2011-05-01T00:00:00Z